FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2182461571> ?p ?o ?g. }

• W2182461571 endingPage "543" @default.
• W2182461571 startingPage "543" @default.
• W2182461571 abstract "SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin Jochen SeufertDepartment of Endocrinology and Diabetology, Clinic for Internal Medicine II, Freiburg University Hospital, Freiburg, GermanyAbstract: Despite the availability of a great variety of medications, a significant proportion of people with type 2 diabetes mellitus (T2DM) are not able to achieve or maintain adequate glycemic control. Beyond improved glucose control, novel treatments would ideally provide a reduction of cardiovascular risk, with a favorable impact on excess weight, and a low intrinsic hypoglycemia risk, as well as a synergistic mechanism of action for broad combination therapy. With the development of sodium glucose cotransporter 2 (SGLT2) inhibitors, an antidiabetic pharmacologic option has recently become available that comes close to meeting these requirements. For the first time, SGLT2 inhibitors offer a therapeutic approach acting directly on the kidneys without requiring insulin secretion or action. Canagliflozin, dapagliflozin, and empagliflozin are the SGLT2 inhibitors approved to date. Taken once a day, these medications can be combined with all other antidiabetic medications including insulin, due to their insulin-independent mechanism of action, with only a minimal risk of hypoglycemia. SGLT2 inhibitors provide additional reductions in body weight and blood pressure due to the therapeutically induced excretion of glucose and sodium through the kidneys. These concomitant effects are particularly interesting with regard to the increased cardiovascular risk in T2DM. In many cases, T2DM treatment requires a multidimensional approach where the treatment goals have to be adapted to the individual patient. While there is a consensus on the use of metformin as a first-line drug therapy, various antidiabetics are used for treatment intensification. New mechanisms of action like that of SGLT2 inhibitors such as canagliflozin, which can be used both in early and late stages of diabetes, are a welcome addition to expand the treatment options for patients at every stage of T2DM. The efficacy and tolerability of canagliflozin have been tested in an extensive clinical trial program described in this review article.Keywords: sodium glucose cotransporter 2 (SGLT2) inhibitor, canagliflozin, dapagliflozin, empagliflozin, type 2 diabetes" @default.
• W2182461571 created "2016-06-24" @default.
• W2182461571 creator A5056074989 @default.
• W2182461571 date "2015-11-01" @default.
• W2182461571 modified "2023-09-24" @default.
• W2182461571 title "SGLT2 inhibitors &ndash; an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin" @default.
• W2182461571 cites W1967064223 @default.
• W2182461571 cites W1968145432 @default.
• W2182461571 cites W1981671332 @default.
• W2182461571 cites W1982905493 @default.
• W2182461571 cites W1987553321 @default.
• W2182461571 cites W1997018189 @default.
• W2182461571 cites W1998397230 @default.
• W2182461571 cites W2000262648 @default.
• W2182461571 cites W2002760082 @default.
• W2182461571 cites W2021988691 @default.
• W2182461571 cites W2031333151 @default.
• W2182461571 cites W2031730303 @default.
• W2182461571 cites W2038270027 @default.
• W2182461571 cites W2047553605 @default.
• W2182461571 cites W2050614267 @default.
• W2182461571 cites W2052526874 @default.
• W2182461571 cites W2064130493 @default.
• W2182461571 cites W2068171948 @default.
• W2182461571 cites W2072209838 @default.
• W2182461571 cites W2076954431 @default.
• W2182461571 cites W2114250030 @default.
• W2182461571 cites W2120600312 @default.
• W2182461571 cites W2120919346 @default.
• W2182461571 cites W2127854619 @default.
• W2182461571 cites W2128050336 @default.
• W2182461571 cites W2130570549 @default.
• W2182461571 cites W2131135469 @default.
• W2182461571 cites W2141800817 @default.
• W2182461571 cites W2144403818 @default.
• W2182461571 cites W2147663252 @default.
• W2182461571 cites W2150453599 @default.
• W2182461571 cites W2154020052 @default.
• W2182461571 cites W2155287847 @default.
• W2182461571 cites W2157405334 @default.
• W2182461571 cites W2159969745 @default.
• W2182461571 cites W2160088494 @default.
• W2182461571 cites W2166823746 @default.
• W2182461571 cites W2168926920 @default.
• W2182461571 cites W2271771390 @default.
• W2182461571 cites W2405206512 @default.
• W2182461571 cites W2460100528 @default.
• W2182461571 cites W39809120 @default.
• W2182461571 doi "https://doi.org/10.2147/dmso.s90662" @default.
• W2182461571 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4644173" @default.
• W2182461571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26609242" @default.
• W2182461571 hasPublicationYear "2015" @default.
• W2182461571 type Work @default.
• W2182461571 sameAs 2182461571 @default.
• W2182461571 citedByCount "50" @default.
• W2182461571 countsByYear W21824615712016 @default.
• W2182461571 countsByYear W21824615712017 @default.
• W2182461571 countsByYear W21824615712018 @default.
• W2182461571 countsByYear W21824615712019 @default.
• W2182461571 countsByYear W21824615712020 @default.
• W2182461571 countsByYear W21824615712021 @default.
• W2182461571 countsByYear W21824615712022 @default.
• W2182461571 countsByYear W21824615712023 @default.
• W2182461571 crossrefType "journal-article" @default.
• W2182461571 hasAuthorship W2182461571A5056074989 @default.
• W2182461571 hasBestOaLocation W21824615711 @default.
• W2182461571 hasConcept C126322002 @default.
• W2182461571 hasConcept C134018914 @default.
• W2182461571 hasConcept C2775887513 @default.
• W2182461571 hasConcept C2777180221 @default.
• W2182461571 hasConcept C2777422806 @default.
• W2182461571 hasConcept C2777451236 @default.
• W2182461571 hasConcept C2779306644 @default.
• W2182461571 hasConcept C2780473172 @default.
• W2182461571 hasConcept C2780668416 @default.
• W2182461571 hasConcept C2910068830 @default.
• W2182461571 hasConcept C555293320 @default.
• W2182461571 hasConcept C71924100 @default.
• W2182461571 hasConcept C90466245 @default.
• W2182461571 hasConcept C98274493 @default.
• W2182461571 hasConceptScore W2182461571C126322002 @default.
• W2182461571 hasConceptScore W2182461571C134018914 @default.
• W2182461571 hasConceptScore W2182461571C2775887513 @default.
• W2182461571 hasConceptScore W2182461571C2777180221 @default.
• W2182461571 hasConceptScore W2182461571C2777422806 @default.
• W2182461571 hasConceptScore W2182461571C2777451236 @default.
• W2182461571 hasConceptScore W2182461571C2779306644 @default.
• W2182461571 hasConceptScore W2182461571C2780473172 @default.
• W2182461571 hasConceptScore W2182461571C2780668416 @default.
• W2182461571 hasConceptScore W2182461571C2910068830 @default.
• W2182461571 hasConceptScore W2182461571C555293320 @default.
• W2182461571 hasConceptScore W2182461571C71924100 @default.
• W2182461571 hasConceptScore W2182461571C90466245 @default.
• W2182461571 hasConceptScore W2182461571C98274493 @default.
• W2182461571 hasLocation W21824615711 @default.
• W2182461571 hasLocation W21824615712 @default.
• W2182461571 hasLocation W21824615713 @default.
• W2182461571 hasLocation W21824615714 @default.

• next